These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 231304)

  • 1. [Treatment of hyperlipidemia type II with soybeans].
    Noseda G; Fragiacomo C; Bosia C; Ramelli F; Sirtori CR
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1852-3. PubMed ID: 231304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Modification of serum lipoproteins by soy bean proteins].
    Richter WO; Weisweiler P; Schwandt P
    MMW Munch Med Wochenschr; 1981 Nov; 123(46):1755-6. PubMed ID: 6796844
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dietary treatment on the plasma levels of lipids, lipoprotein cholesterol and LDL B protein in children with type II hyperlipoproteinemia.
    Kwiterovich PO; Bachorik PS; Franklin FA; Margolis S; Georgopoulos L; Teng B; Sniderman AD
    Prog Clin Biol Res; 1985; 188():123-37. PubMed ID: 4059254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
    Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
    Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.
    Homma Y; Kobayashi T; Yamaguchi H; Sakane H; Ozawa H; Matsuda M; Mikami Y; Mikami Y; Nakamura H
    Artery; 1993; 20(1):1-18. PubMed ID: 8447724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical research on the hypolipidemic action of a probucol preparation].
    Naumova R; Kerekovska M; Goranov I; Balabanski L
    Vutr Boles; 1986; 25(2):73-7. PubMed ID: 3716382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the purified unsaponifiable fraction of soybean on primary type II hyperlipoproteinemia.
    Nakashima Y; Nakamura T; Aramaki Y; Kuroiwa A
    Artery; 1983; 12(3):199-211. PubMed ID: 6687319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of a purified bran preparation in men with low HDL cholesterol.
    Lithell H; Selinus I; Vessby B
    Hum Nutr Clin Nutr; 1984 Jul; 38(4):309-13. PubMed ID: 6088439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
    Herrmann W; Reuter W
    Z Gesamte Inn Med; 1982 Dec; 37(24):830-3. PubMed ID: 6963524
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of dyslipidaemia with a simple low fat diet and with a combination of a low fat diet and a formulation containing soybean protein.
    Pesciatini F; Cefis M; Lazzaroni A; Pansera P; Cerri B
    Int J Clin Pharmacol Res; 1985; 5(3):199-204. PubMed ID: 4018955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soybean protein independently lowers plasma cholesterol levels in primary hypercholesterolemia.
    Goldberg AP; Lim A; Kolar JB; Grundhauser JJ; Steinke FH; Schonfeld G
    Atherosclerosis; 1982 Jun; 43(2-3):355-68. PubMed ID: 6889432
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(12):1682-4. PubMed ID: 6686774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid results of partial ileal bypass in patients with heterozygous, type II-A hyperlipoproteinemia. Program on the Surgical Control of the Hyperlipidemias.
    Campos CT; Matts JP; Fitch LL; Speech JC; Long JM; Buchwald H
    Surgery; 1990 Oct; 108(4):601-10; discussion 610-1. PubMed ID: 2120785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinico-experimental approaches to studying the hypocholesteremic action of soy proteins].
    Liapkov BG; Iatsyshina TA; Fedotova NIu; Kalamkarova OM
    Vopr Pitan; 1986; (2):39-43. PubMed ID: 3705542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
    Wechsler JG; Hutt V; Klör HU; Ditschuneit H
    Artery; 1980; 8(6):519-29. PubMed ID: 7259531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.